INAB vs. HCWB, SGTX, ORPH, TTOO, ENLV, OTLK, VCXB, XFOR, CRDL, and KOD
Should you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include HCW Biologics (HCWB), Sigilon Therapeutics (SGTX), Orphazyme A/S (ORPH), T2 Biosystems (TTOO), Enlivex Therapeutics (ENLV), Outlook Therapeutics (OTLK), 10X Capital Venture Acquisition Corp. III (VCXB), X4 Pharmaceuticals (XFOR), Cardiol Therapeutics (CRDL), and Kodiak Sciences (KOD). These companies are all part of the "medical" sector.
IN8bio (NASDAQ:INAB) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.
In the previous week, IN8bio had 2 more articles in the media than HCW Biologics. MarketBeat recorded 5 mentions for IN8bio and 3 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 1.59 beat IN8bio's score of 0.19 indicating that HCW Biologics is being referred to more favorably in the news media.
IN8bio currently has a consensus target price of $10.00, suggesting a potential upside of 870.87%. Given IN8bio's higher probable upside, research analysts plainly believe IN8bio is more favorable than HCW Biologics.
IN8bio received 14 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 68.97% of users gave IN8bio an outperform vote.
HCW Biologics has higher revenue and earnings than IN8bio. HCW Biologics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.
92.1% of IN8bio shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 15.5% of IN8bio shares are held by company insiders. Comparatively, 49.9% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
IN8bio has a net margin of 0.00% compared to HCW Biologics' net margin of -697.53%. HCW Biologics' return on equity of -146.76% beat IN8bio's return on equity.
IN8bio has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.
Summary
HCW Biologics beats IN8bio on 9 of the 16 factors compared between the two stocks.
Get IN8bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
